SynOx Therapeutics Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SynOx Therapeutics Ltd.
Forbion Eyes Late-Stage Opportunities With New Fund
Looking to take advantage of the cool reception private biotechs are receiving from the public markets, a leading European VC is targeting investments of up to €70m per deal in firms with undervalued late-stage assets.
Finance Watch: Biotech Venture Capital Had Its Biggest Quarter Ever
Private Company Edition: VC mega-rounds boosted the Q1 2021 total. Also, new funds from Versant, The Column Group and Rapha Capital keep cash flowing into biopharma; up to $525m is invested in Exscientia; and Arch Oncology and Boundless Bio raised $105m each, while Forge brought in $120m.
- Large Molecule
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.